doi: 10.3389/fcell.2025.1514636 Received 21 October 2024 Accepted 03 February 2025 Published 26 February 2025 Volume 13 - 2025 Edited by Dexi Bi, Tongji University, China Reviewed by Hussam Askar, Al Azhar University, Egypt Xinjun Wang, Tongji University, China Updates Copyright 2025 Ullah, Arbab, Chang, Bibi, Muhammad, Rehman, Suleman, Ullah, Hassan, Tian and Li
ACSL4 is responsible for esterifying PUFAs into their corresponding acyl-CoA derivatives, after which LPCAT3 catalyzes the incorporation of these activated PUFAs into membrane phospholipids to form phospholipid-containing polyunsaturated fatty acids (PL-PUFAs) (14)
Sources: Lillys oral GLP-1, Orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal phase 3 trials in adults with obesity | Eli Lilly and Company
The process is not without its complexities, but with meticulous dosage adjustments, monitoring, and side effect management, it can lead to a seamless and successful changeover